Ascension Sciences Announces Creation of Advisory Board
VANCOUVER, September 28th, 2020 — Ascension Sciences Inc. (“ASI”), an independent laboratory focused on nanoparticle development for cannabinoid products and therapeutics, is pleased to announce the creation of an Advisory Board and welcome two Scientific Advisors, Dr. Tomaž Einfalt and Dr. Pierrot Harvie. The strategic insights from these industry experts will help ASI execute on both internal and client nanoparticle formulation therapies.
As Scientific Advisors, Dr. Einfalt and Dr. Harvie have important roles in advancing the R&D interests of Ascension Sciences and, where relevant, contributing to the business strategy by providing counsel to the CEO and scientists on matters related to growing and enhancing the company.
Dr. Einfalt did his undergraduate studies as a pharmacist at the Faculty of Pharmacy, University of Ljubljana. During this time, he participated in research exchanges focused on the development and characterization of nano-pharmaceutical delivery systems. In 2017, he received his doctorate in nanosciences from the University of Basel, where he is currently employed as an operational lead. His expertise lies in pharmaceutical technology nano-drug delivery, and his research work has led to several breakthrough discoveries, patent applications and academia-industry collaborations.
Dr. Harvie brings 20 years of experience working as a formulation and process scientist in the biotechnology industry. Recently, he was a Senior Scientist at Genevant Sciences, and prior to that he worked 5 years as an Associate Director at PhaseRx, Inc. Other career highlights include working as a formulation scientist at Marina Biotech, Celator Pharmaceuticals and Targeted Genetics. He is the author of seven US patents and 20 peer reviewed papers. He holds a Ph.D. in Microbiology and Immunology from Université Laval, a M.Sc. in Microbiology and Immunology, Université de Montréal, and B.Sc. in Medical Biology, University of Quebec.
“Dr. Harvie and Dr. Einfalt are both well respected the nano and biotechnology community and will make invaluable additions to our Advisory Board,” commented Tomas Skrinskas, Founder & CEO of Ascension Sciences, “We’re excited for them to join us and know that Ascension Sciences will greatly benefit from their strategic counsel.”
For media inquiries, please contact [email protected]. Stay connected with ASI on LinkedIn and Twitter for the latest news.
Employing nanoparticle formulation technology from the cutting edge of genetic medicine, Ascension Sciences is developing cannabinoid nano delivery platforms and techniques for the pharma and nutraceutical industries. Liposomes, nanoemulsions, lipid nanoparticles and polymeric nanoparticles have all shown promise in improving the therapeutic benefits of cannabinoids, but the full potential of these therapies has not yet been unlocked.
Our R&D and formulation development services are an efficient option for research driven firms that require the advantages of nanoparticle delivery for their active ingredients. We work with other passionate researchers in the industry that share a common goal of improving the human condition and bringing novel therapies to those who need them most.
For more information, please visit: https://ascensionsciences.com/